Angiotech Suspends Drug-Eluting Vascular Wrap Trials Over Safety Signals
This article was originally published in The Gray Sheet
Executive Summary
Angiotech suspended enrollment April 21 in U.S. and European pivotal trials of its drug-eluting vascular graft mesh wrap due to safety concerns
You may also be interested in...
Angiotech Seeks Partner For Stalled Vascular Wrap R&D Program
Combination product developer Angiotech is looking for someone to help fund its stalled drug-eluting Vascular Wrap R&D program as part of a broader effort to return to profitability by year-end
Angiotech Seeks Partner For Stalled Vascular Wrap R&D Program
Combination product developer Angiotech is looking for someone to help fund its stalled drug-eluting Vascular Wrap R&D program as part of a broader effort to return to profitability by year-end
With AMI Buy, Angiotech Looks To Become Less Reliant On Partnerships
Angiotech Pharmaceuticals' $785 mil. acquisition of American Medical Instruments Holdings will allow the firm to diversify its revenue stream and retain more control over its combination product business